Recent Updates
Recently added Catalysts
MLYS Positive Sentiment Score: 70/100

Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023

Key Takeaway: Mineralys Therapeutics, a clinical-stage biopharmaceutical company, will participate in the Wells Fargo Securities Healthcare Conference on September 7, 2023. CEO Jon Congleton and CFO Adam Levy will engage in a fireside chat to discuss the company's developments. Mineralys is focused on treating diseases associated with elevated aldosterone, and its lead candidate, lorundrostat, aims to address cardiorenal conditions. The event offers a platform to increase awareness of their innovative treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a notable healthcare conference enhances visibility.
  • Opportunity for leadership to discuss innovative treatments.
  • Cementing Mineralys' position in the biopharma industry.

Full Press Release Details

RADNOR, Pa., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will participate in a fireside chat at the Wells Fargo Securities Healthcare Conference in Boston, Massachusetts on Thursday, September 7, 2023 at 8:45 a.m. ET.
The live webcast of the fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcast will be available on the Company’s website for approximately 90 days.
Wells Fargo Securities Healthcare Conference:
Date: Thursday, September 7, 2023
Time: 8:45 a.m. ET
Webcast Link
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Elixir Health Public Relations
Phone: (1) 515-707-9678

Frequently Asked Questions

What is the focus of Mineralys Therapeutics?

Mineralys Therapeutics develops medicines targeting diseases caused by elevated aldosterone.

When is the Wells Fargo Healthcare Conference?

The conference is on September 7, 2023, at 8:45 a.m. ET.

How can I access the fireside chat webcast?

The webcast can be accessed on the Investor Relations section of their website.

What is lorundrostat used for?

Lorundrostat is an aldosterone synthase inhibitor for cardiorenal conditions.

Where is Mineralys Therapeutics based?

Mineralys Therapeutics is based in Radnor, Pennsylvania.

Last updated: Aug 29, 2023